WEST

Generate Collection Print

L1: Entry 3 of 5

File: USPT

Mar 28, 2000

US-PAT-NO: 6043094

DOCUMENT-IDENTIFIER: US 6043094 A

TITLE: Therapeutic liposome composition and method

DATE-ISSUED: March 28, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Martin; Francis J. San Francisco CA
Zalipsky; Samuel Redwood City CA
Huang; Shi Kun Castro Valley CA

ASSIGNEE-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY TYPE CODE

Sequus Pharmaceuticals, Inc. Menlo Park CA 02

APPL-NO: 08/ 949039 [PALM]
DATE FILED: October 10, 1997

PARENT-CASE:

THERAPEUTIC LIPOSOME COMPOSITION AND METHOD This application claims the benefit of U.S. Provisional Application No. 60/027,923, filed Oct. 11, 1996, incorporated herein by reference in its entirety.

INT-CL: [07] C12 N 15/64, A61 K 9/127

US-CL-ISSUED: 435/458; 424/450, 435/375, 530/402, 530/403 US-CL-CURRENT: 435/458; 424/450, 435/375, 530/402, 530/403

FIELD-OF-SEARCH: 424/450, 424/9.321, 424/417, 424/420, 424/94.3, 424/812, 424/9.1, 424/9.2, 264/4.1, 436/829, 514/2, 514/44, 435/455, 435/458, 435/476, 435/366,

435/375, 530/402, 530/403, 530/387.1, 530/391.9

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected Search ALL

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
4935465	June 1990	Garman	525/54.1
5013556	May 1991	Woodle et al.	424/450

FOREIGN PATENT DOCUMENTS

OTHER PUBLICATIONS

International Search Report for PCT Application No. PCT/US97/18813 (Mar. 11, 1998). Allen, T.M. et al., "A New Strategy for Attachment of Antibodies to Sterically Stabilized Liposomes Resulting in Efficient Targeting to Cancer Cells," Biochimica et Biophysica Acta. 1237: 99-108 (1995).

Blume, G. et al., "Specific Targeting with Poly(Ethylene Glycol)-Modified Liposomes: Coupling of Homing Devices to the Ends of the Polymeric Chains Combines Effective Target Binding with Long Circulation Times," Biochimica et Biophysica Acta. 1149: 180-184 (1993).

DeFrees, S.A. et al., "Sialyl Lewis x Liposomes as a Multivalent Ligand and Inhibitor of E-Selectin Mediated Cellular Adhesion," J. Am. Chem. Soc. 118: 6101-6104 (1996). Kirpotin, D. et al., "Liposomes with Detachable Polymer Coating: Destabilization and Fusion of Dioleoylphosphatidylethanolamine Vesicles Triggered by Cleavage of Surface-Grafted Poly(Ethylene Glycol)," FEBS Letters. 388: 115-118 (1996). Klibanov, A.L. and Huang, L., "Long-Circulating Liposomes: Development and Perspectives," Journal of Liposome Research. 2:(3) 321-334 (1992). Zalipsky, S. et al., "Long Circulating, Cationic Liposomes Containing Amino-PEG-Phosphatidylethanolamine," FEBS Letters. 353: 71-74 (1994). Zalipsky, S., "Polyethylene Glycol-Lipid Conjugates" in Stealth Liposomes. eds. Lasic, D. and Martin, F., CRC Press, Inc., Fla.. 1995, pp. 93-102. Zalipsky, S., "Synthesis of an End-Group Functionalized Polyethylene Glycol-Lipid Conjugate for Preparation of Polymer-Grafted Liposomes," Bioconjugate Chem. 4:(4) 296-299 (1993).

Haynes. Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development. Science. 260: 1279-1286, 1993.

Bone. The Pathogenesis of Sepsis. Annals of Internal Medicine. 115 (6): 457-469, Sep. 15, 1991.

ART-UNIT: 166

PRIMARY-EXAMINER: Brusca; John S.

ASSISTANT-EXAMINER: Shuman; Jon D.

ABSTRACT:

A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating effective to shield the affinity moiety from interaction with the target surface. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components in the liposomes through releasable linkages. After a desired liposome biodistribution is achieved, a releasing agent is administered to cause cleaving of a substantial portion of the releasable linkages in the liposomes, to expose the affinity agent to the target surface.

17 Claims, 9 Drawing figures

WEST

Generate Collection

Print

Search Results - Record(s) 1 through 5 of 5 returned.

☐ 1. Document ID: US 6248720 B1

L1: Entry 1 of 5

File: USPT

Jun 19, 2001

US-PAT-NO: 6248720

DOCUMENT-IDENTIFIER: US 6248720 B1

TITLE: Method for gene therapy using nucleic acid loaded polymeric microparticles

DATE-ISSUED: June 19, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Mathiowitz; Edith

Brookline

MA

Jong; Yong S.

Warwick Providence RI RI

Carino; Gerardo Jacob; Jules S.

Taunton

MA

US-CL-CURRENT: 514/44; 424/489, 424/490, 424/497, 435/320.1, 435/455

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw Desc Image

☐ 2. Document ID: US 6120799 A

L1: Entry 2 of 5

File: USPT

Sep 19, 2000

US-PAT-NO: 6120799

DOCUMENT-IDENTIFIER: US 6120799 A

TITLE: Cationic lipid compositions targeting angiogenic endothelial cells

DATE-ISSUED: September 19, 2000

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

McDonald; Donald M.

San Francisco

CA

McLean; John

Redwood City

CA

Thurston; O. Gavin

San Francisco

CA

Baluk; Peter San Francisco

CA

US-CL-CURRENT: 424/450

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw, Desc Image

3. Document ID: US 6043094 A

L1: Entry 3 of 5

File: USPT

Mar 28, 2000

US-PAT-NO: 6043094

DOCUMENT-IDENTIFIER: US 6043094 A

TITLE: Therapeutic liposome composition and method

DATE-ISSUED: March 28, 2000

INVENTOR - INFORMATION:

NAME CITY · STATE ZIP CODE COUNTRY

Martin; Francis J. San Francisco CA
Zalipsky; Samuel Redwood City CA
Huang; Shi Kun Castro Valley CA

US-CL-CURRENT: 435/458; 424/450, 435/375, 530/402, 530/403

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Clarims | KMC |
Draw Desc | Image |

4. Document ID: US 5837283 A

L1: Entry 4 of 5

File: USPT

Nov 17, 1998

US-PAT-NO: 5837283

DOCUMENT-IDENTIFIER: US 5837283 A

TITLE: Cationic lipid compositions targeting angiogenic endothelial cells

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

McDonald; Donald M. San Francisco CA
McLean; John Redwood City CA
Thurston; O. Gavin San Francisco CA
Baluk; Peter San Francisco CA

US-CL-CURRENT: 424/450

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draws Desc Image

5. Document ID: WO 9840052 A1 US 5837283 A AU 9864613 A NO 9904413 A BR 9808018 A EP 1014945 A1 US 6120799 A AU 727946 B KR 2000076182 A MX 9908343 A1 JP 2001509816 W US 20020155102 A1

L1: Entry 5 of 5

File: DWPI

Sep 17, 1998

DERWENT-ACC-NO: 1998-520784

DERWENT-WEEK: 200278

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Inhibitor/lipid complexes for, e.g. treatment of inflammation - comprise cationic lipid(s) and inhibitor of angiogenesis and have, in blood, high affinity for angiogenic endothelial cells

INVENTOR: BALUK, P; MCDONALD, D M ; MCLEAN, J ; THURSTON, O G ; MACDONALD, D M ; MCCLEAN, J

PRIORITY-DATA: 1997US-0820337 (March 12, 1997), 1998US-0127177 (July 31, 1998), 1999US-0429071 (October 29, 1999), 2002US-0160714 (May 29, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9840052 A1	September 17, 1998	E	068	A61K009/127
US 5837283 A	November 17, 1998		000	A61K009/127
AU 9864613 A	September 29, 1998		000	A61K009/127
NO 9904413 A	November 10, 1999		000	A61K000/00
BR 9808018 A	March 8, 2000		000	A61K009/127
EP 1014945 A1	July 5, 2000	E	000	A61K009/127
US 6120799 A	September 19, 2000		000	A61K009/127
AU 727946 B	January 4, 2001		000	A61K009/127
KR 2000076182 A	December 26, 2000		000	A61K009/127
MX 9908343 A1	August 1, 2000		000	A61K009/127
JP 2001509816 W	July 24, 2001		076	A61K045/06
US 20020155102 A1	October 24, 2002		000	A61K038/48

INT-CL (IPC): $\underline{A61}$ \underline{K} $\underline{0/00}$; $\underline{A61}$ \underline{K} $\underline{9/00}$; $\underline{A61}$ \underline{K} $\underline{9/00}$; $\underline{A61}$ \underline{K} $\underline{9/127}$; $\underline{A61}$ \underline{K} $\underline{31/7088}$; $\underline{A61}$ \underline{K} $\underline{38/48}$; $\underline{A61}$ \underline{K} $\underline{45/06}$; $\underline{A61}$ \underline{K} $\underline{49/00}$; $\underline{A61}$ \underline{P} $\underline{35/00}$; $\underline{G01}$ \underline{N} $\underline{33/50}$

Full		Citation		Review	Classification	Date	Reference	Sequences	Attachments	KWC
atro. C	eso C	lip Img Ir	nage							
					Generate	Collec	tion	Print		
				1		0000				
					Terms				Docume	nts
(cationic adj1 liposome\$) same label										5

Display Format: - Change Format

Previous Page Next Page

Generate Collection Print

L4: Entry 30 of 42 File: USPT Apr 6, 1999

DOCUMENT-IDENTIFIER: US 5891689 A

TITLE: Heme-bearing microparticles for targeted delivery of drugs

Detailed Description Text (35):

A variety of drugs and compounds can be delivered to specific cells and organs using heme-bearing microparticles, including nucleic acid-based compounds, such as ribozymes and antisense oligonucleotides, proteins, carbohydrates, synthetic organic and inorganic molecules, monitoring agents, and combinations thereof, referred to herein as "therapeutic compounds" unless otherwise specified. In the preferred embodiment, the therapeutic compounds are nucleic acids, especially ribozymes, antisense oligonucleotides, aptamers, triplex molecules and antisense oligonucleotides. Examples of compounds falling within this group include DNA and RNA for transfection, and compounds to Label intracellular molecules, as described, for example, by Felgner et al., Proc. Natl. Acad. Sci. USA, 84, 7413-7417; Lee et al., Biochim. Biophys. Acta, 1103, 185-197 (1992). Any therapeutic or function-enhancer could be incorporated, for instance, any liver enzyme for which there is a deficiency could be delivered using the heme system.

Detailed Description Text (40):

Alteratively, <u>cationic liposomes</u> can be prepared by using mixtures including one or more lipids containing a cationic side group in a sufficient quantity such that the liposomes formed from the mixture possess a net positive charge which will ionically bind negatively charged compounds. <u>Cationic liposomes</u> have a great capacity for association with nucleic acids. Studies demonstrate that 4 .mu.g lipid (dioleoyl trimethylammonium propane:dioleoyl phospatidylethanolamine 1:1 molar mixture) binds at least 1 .mu.g DNA, and that this was 100% of the added dose, implying that this lipid was not saturated. This is representative of the binding stoichiometry of DNA to most postively charged lipids.

Detailed Description Text (41):

Examples of positively charged lipids that may be used to produce <u>cationic liposomes</u> include the aminolipid dioleoyl PE, which possesses a positively charged primary amino head group; phosphatidylcholines, which possess positively charged head groups which are not primary amines; and the recently designed N[1-(2,3-dioleyloxy)propyl]-N,N,N-triethylammonium ("DOTMA," described by Felgner, P. L. et al., Proc. Natl. Acad. Sci USA, 84, 7413-7417 (1987); Felgner, P. L. et al., Nature, 337, 387-388 (1989); Felgner, P. L., Advanced Drug Delivery Reviews, 5, 163-187 (1990)).

Detailed Description Text (42):

Cationic liposomes are particularly useful for delivering negatively charged compounds such as nucleic acid-based compounds, which bind ionically to the positively charged outer surface of these liposomes. Various cationic liposomes have previously been shown to be very effective at delivering nucleic acids or nucleic acid-protein complexes to cells both in vitro and in vivo, as reported by Felgner, P. L. et al., Proc. Natl. Acad. Sci. USA, 84, 7413-7417 (1987); Felgner, P. L., Advanced Drug Delivery Reviews, 5, 163-187 (1990); Clarenc, J. P. et al., Anti-Cancer Drug Design, 8, 81-94. Following association of the DNA with the preformed cationic liposome, it has been hypothesized that the membranes realign and form complexes entrapping the added nucleic acid possibly by fusion of adjacent liposomes.

<u>Detailed Description Text (43):</u>

The <u>cationic liposomes</u> can be conjugated or intercalated with heme, as described above, before, or preferably, after incorporation of compound. For example, heme-bearing <u>cationic liposomes</u> can be mixed with a negatively charged drug or other compound, which will then complex with the surface of the liposomes ionically via positive charge-negative charge interactions.

<u>Current US Cross Reference Classification</u> (1): 424/450

CLAIMS:

- 7. The method of claim 6 wherein the liposome is a cationic liposome.
- 16. The method of claim 15 wherein the liposome is a cationic liposome.
- 24. The liposome of claim 23 wherein the liposome is a cationic liposome.

DAR	A 100 Per 19 Per	1	10.00
	22.000		
100	2	20.7	
	B = 20	w	

End of Result Set

Generate Collection Print

L4: Entry 42 of 42

File: USPT

Aug 4, 1987

DOCUMENT-IDENTIFIER: US 4684625 A

TITLE: Method for enhancing the anti-infective activity of muramyldipeptide

derivatives


Brief Summary Text (76):

The liposomes may be anionic, basic or neutral depending upon the choice of hydrophilic group. For instance, when a phosphate or a sulfate group is used the resulting liposome will be anionic. When amino-containing surfactants are used, the liposomes will have a positive charge, or be cationic liposomes, and when polyethyleneoxy or glycol groups are present in the surfactant, neutral liposomes will be obtained. Compounds suitable for forming liposomes may be found in references including McCutcheon's Detergents and Emulsifiers and McCutcheon's Functional Materials, Allured Pub. Company, Ridgewood, N.J., U.S.A.

Detailed Description Text (8):

MLVs were prepared as described above, hydrating the dried lipid film with PBS. These pre-formed liposomes were then mixed with unencapsulated MDP compound spiked with tritiated N-acetyldesmethylmuramyl-L-alanyl-D-isoglutamine (.sup.3 H-desMDP). The liposome/MDP derivative mixture was washed and pelleted, and the final liposome pellet resuspended in PBS. The radioactivity in the liposome fraction was determined, as well as the radioactivity in the aqueous supernatant from the washing and pelleting steps. The results are presented in Table III. These results show that essentially 100% of the .sup.3 H label remained in the supernatant and was not incorporated into the liposomes. Thus, MDP compounds are not incorporated into or attached to liposomes in the practice of the invention.

<u>Current US Cross Reference Classification</u> (1): 424/450



L4: Entry 41 of 42 File: USPT Nov 24, 1987

DOCUMENT-IDENTIFIER: US 4708861 A TITLE: Liposome-gel compositions

Brief Summary Text (51):

Most amphipathic lipids may be constituents of SPLVs. Suitable hydrophilic groups include but are not limited to: phosphato, carboxylic, sulphato and amino groups. Suitable hydrophobic groups include but are not limited to: saturated and unsaturated aliphatic hydro-carbon groups and aliphatic hydrocarbon groups substituted by at least one aromatic and/or cycloaliphatic group. The preferred amphipathic compounds are phospholipids and closely related chemical structures. Examples of these include but are not limited to: lecithin, phosphatidyl-ethanolamine, lysolecithin, lysophatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid and the cerebrosides. Specific examples of sultable lipids useful in the production of SPLVs are phospholipids which include the natural lecithins (e.g., egg lecithin or soybean lecithin) and synthetic lecithins, such as saturated synthetic lecithins (e.g., dimyristoylphosphatidylcholine, or dipalmitoylphosphatidylcholine or distearoyl-phosphatidylcholine) and unsaturated synthetic lecithins (e.g., dioloylphosphatidylcholine or dilinoloyl-phosphatidylcholine). The SPLV bilayers can contain a steroid component such as cholesterol, coprostanol, cholestanol, cholestane and the like. When using compounds with acidic hydrophilic groups (phosphato, sulfato, etc.) the obtained SPLVs will be anionic; with basic groups such as amino, cationic liposomes will be obtained; and with polyethylenoxy or glycol groups neutral liposomes will be obtained. The size of the SPLVs varies widely. The range extends from about 100 nm to about 10,000 nm (10 microns) and usually about 100 nm to about 1,500 nm. The SPLVs are characterized by a few to over 100 lipid bilayers enclosing aqueous compartments.

Brief Summary Text (59):

Specific examples of suitable lipids useful in the production of MPVs are phospholipids which include but are not limited to the natural lecithins or phosphatidylcholines (e.g., egg lecithin or soybean lecithin) and synthetic lecithins, such as saturated synthetic lecithins (e.g., dimyristoylphosphatidylcholine or dipalmitoylphosphatidylcholine or distearoylphosphatidylcholine) and unsaturated synthetic lecithins (e.g., dioleoylphosphatidylcholine) or dilinoleoylphosphatidylcholine). Other phospholipids include but are not limited to phosphatidylethonolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, ceramides and the cerebrosides. The MPV bilayers can contain a steroid component such as cholesterol, coprostanol, cholestanol, cholestane and the like. When using compounds with acidic hydrophilic groups (phosphato, sulfato, etc.) the obtained MPVs will be anionic; with basic groups such as amino, cationic liposomes will be obtained.

Detailed Description Text (43):

SPLVs containing insulin (insulin/SPLVs) were prepared as described in Section 4.1: 100 mg dipalmitoyl phosphatidylcholine was dissolved in 5 ml diethyl ether. To this was added 0.3 ml of aqueous buffer (either PBS or 0.01M Tris) at pH 7.4. containing 15 mg bovine insulin (25 unit/mg) (Sigma Chemical CO., St. Louis, MO). In order to solubilized the insulin in the aqueous buffer, it was necessary first to partition the hormone powder into a solution (50 mg/ml) of sonicated small unilamellar vesicles composed of EPC. Following solubilization, the aqueous droplet was emulsified into

the ether phase by sonicating under a stream of nitrogen until the ether was completely evaporated. The lipid/insulin paste was rehydrated to form insulin/SPLVs. The insulin/SPLVs were washed three times in buffer containing 10 mm CaCl.sub.2. The CaCl.sub.2 facilitated pelleting of the insulin/SPLVs. Entrapment of insulin as determined by .sup.14 C-insulin label was 20-30%.

<u>Current US Cross Reference Classification</u> (4): 424/450

WEST

Print

L4: Entry 38 of 42

File: USPT

Sep 3, 1996

DOCUMENT-IDENTIFIER: US 5552155 A

TITLE: Fusogenic lipsomes and methods for making and using same

Detailed Description Text (59):

Membrane fusion was monitored by a loss in RET between the fluorescently labeled lipids NBD-PE and Rh-PE. When liposomes containing both of these <u>labels</u> fuse with unlabeled liposomes, the resulting dilution of the fluorescent probes gives increased fluorescence for NBD-PE. Appreciable exchange of these labeled lipids between liposomes does not appear to occur even in aggregated systems, and fluorescence increases only upon mixing of membrane lipids.

Generate Collection

Detailed Description Text (60):

The use of the fluorescent probe dilution assay to demonstrate fusion in LUVs containing 10 mole % AL-1 is depicted in FIGS. 3 and 4. Unlabeled and labeled liposomes (3:1) comprising EPC/Chol (55:45) with no AL-1 showed no increase in fluorescence upon dissipation of the pH gradient. A small decrease in fluorescence was observed due to the addition of the ammonium solution. Similar liposomes containing 10 and 20 mole % AL-1 gave a rapid increase in fluorescence which leveled out quickly at a value of .DELTA.F/.DELTA.F.sub.max near 3%. This represents only a limited amount of the total possible lipid mixing which for 3:1 mixtures of unlabeled and labeled liposomes should give a .DELTA.F/.DELTA.F.sub.max of 80%, as determined by preparing liposomes with the fluorescent labels at one quarter of the normal concentration (0.18 mole %). The low fluorescence increase observed indicates that, while AL-1 can induce pH gradient-controlled fusion in EPC/Chol liposomes, its ability to do so is limited. For AL-1 concentrations greater than about 20 mole %, in EPC/Chol liposomes, rapid and complete liposome aggregation was observed following extrusion.

<u>Current US Original Classification</u> (1): 424/450

Other Reference Publication (13):

Konopka, et al., "Enhancement of human immunodeficiency virus type 1 infection by cationic liposomes: the role of CD4, serum and liposome-cell interactions", J. Gen Virol, 72: 2685-2696, 1991.

Other Reference Publication (15):

Malone, et al., "Cationic Liposome-Mediated RNA Transfection", Proc. Natl. Acad. Sci, 86: 6077-6081, 1989.

Generate Collection Print

L4: Entry 35 of 42 File: USPT Jul 14, 1998

DOCUMENT-IDENTIFIER: US 5780052 A

TITLE: Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell

Detailed Description Text (22):

Antibodies, and in particular monoclonal antibodies, are the focus of intense interest in the field of cancer research. Antibodies have been developed to cell-surface antigens for a number of malignancies, but are useful only in restricted categories of tumors. Techniques are known for conjugating such antibodies to pharmacologically active agents or to Labels to permit diagnosis, localization, and therapy directed toward such tumors.

Detailed Description Text (40):

Liposome/drug formulations are characterized by measurements of particle size, lipid concentration, and pH by standard methods as described above. Drug incorporation into the composition may be determined by inclusion of radiolabeled tracer in the composition. The amount of liposome-entrapped drug is then determined by gel permeation chromatography using BioRad A-15M resin. The liposomal drug fraction is calculated from the amount of radiolabel present in the void volume of the column, and the percentage of liposomal drug from the ratio of label eluting in the void volume to the remaining label eluting from the column.

Detailed Description Text (52):

Labeling and Labels Useful in the Invention

Detailed Description Text (53):

The various <u>labels</u> listed below need not be limited to labeling of antibodies. Instead of antibodies, other carriers (synthetic or natural) may be used as recipients of the labels.

Detailed Description Text (59):

Radiopaque materials also may be used to label the antibodies. Suitable radiopaque materials are well known and include iodine compounds, barium compounds, gallium compounds, thallium compounds, and the like. Specific examples of radiopaque materials include barium, diatrizoate, ethiodized oil, gallium citrate, iocarmic acid, iocetamic acid, iodamide, iodipamide, iodoxamic acid, iogulamide, iohexol, iopamidol, iopanoic acid, iotasul, iotetric acid, iothalamic acid, iotroxic acid, ioxaglic acid, ioxotrizoic acid, ipodate, meglumine, metrizamide, metrizoate, propyliodone, and thallous chloride.

Detailed Description Text (62):

Conjugation of Labels and Therapeutic Compounds to Antibodies or Other Carriers

Detailed Description Text (91):

One diagnostic procedure of the present invention involves diagnosing sites of necrosis in an organ or tissue. This procedure utilizes immunoliposomes specific for intracellular antigens and containing a diagnostic agent, e.g., a detectable molecule such as an imaging agent. One example of such an agent is a gamma-emitting radionuclide of the type previously discussed. The radionuclide may be attached to a convenient carrier molecule, such as a chelating polymer. The radionuclide-containing immunoliposome is injected (preferably intravenously) into a patient suspected of containing an organ or tissue that is undergoing cell death; for example, a patient

who has received chemotherapy, radiation therapy, or both. This procedure is preferably carried out at least one or two days after the initiation of the therapy, in order to permit resultant necrosis of the neoplastic tissue to advance to a sufficient point that reasonable numbers of necrotic cells are present. Between 30 minutes and 3 days following administration of the labeled antibody, an appropriate scintigraphic imaging technique is employed to image the Label that is localized in necrotic tissue. Suitable imaging techniques include gamma cameras and SPECT (single photon emission computed tomography) techniques.

Detailed Description Text (119):

A monoclonal antimyosin antibody was generated by hybridization of immune murine spleen cells with SP2/OA murine myeloma cells, purified by methods previously described (Khaw et al., Hybridoma 3:11-23, 1984, hereby incorporated by reference), and numbered 2G42D7 (as referred to herein). The bicyclic anhydride of diethylenetriamine pentaacetic acid (DTPA) is prepared by the method of Hnatowich et al. (Hnatowich et al., Science 220:613-615, 1983, hereby incorporated by reference) for coupling with antimyosin-Fab. The molar ratio of DTPA to Fab was 1:1. Two approaches may be used to label antimyosin Fab, .sup.111 In coupling to the DTPA and .sup.123 I coupling directly to the protein using chloramine-T.

Detailed Description Text (121):

Approximately 37 MBq (1 mCi) of .sup.111 InCl is used to <u>label</u> 100 .mu.g of DTPA-R11D10-Fab. To a 1-mCi aliquot (50 .mu.l) of .sup.111 InCl, an equal volume of 1M sodium citrate (pH 5.5) is added, followed by an aliquot of antimyosin-Fab. The reaction mixture is allowed to incubate at room temperature for 30 min. Antibody-bound .sup.111 In is separated from free .sup.111 In by SEPHADEX (Sigma Chemical, St. Louis, Mo.) G-25 column (10 ml) chromatography. The peak tubes in the void volume containing the radiolabled antibody are pooled and used within 1 hour of radiolabeling. An average of 80% of the initial antibody concentration is recovered in the peak tubes containing the radiolabeled antibody.

<u>Detailed Description Text</u> (123):

Radioiodination is accomplished by the chloramine-T method, as described by Hunter and Greenwood (Hunter et al., Nature 194:495-496, 1962) to label antimyosin Fab with .sup.123 I. To a 100 .mu.g aliquot of DTPA-coupled antimyosin Fab antibody in 0.1M phosphate buffer (pH 7.4), 37 MBq (1 mCi) of .sup.123 I is added and mixed thoroughly. A 10-.mu.l aliquot of chloramine-T (26 mg/ml in 0.5M phosphate buffer, pH 7.4) is added followed by mixing for 2 min. Iodination is terminated by the addition of 25 .mu.l of 0.1M methionine plus 0.1M cresol. The reaction mixture is then applied to a 10-ml SEPHADEX G-25 column to separate free and protein-bound radioiodine.

Detailed Description Text (127):

Several methods have been used for the delivery of DNA into cells, including poly-L-lysine conjugated lipids (Zhou et al., Biochim. Biophys. Acta. 1065:8-14, 1991), pH sensitive immunoliposomes (Gregoriadis, G., Liposome Technology, Vol I, II, III, CRC, 1993), and cationic liposomes (Felgner et al., Proc. Natl. Acad. Sci., USA, 84:7413-7417, 1987). However, the drawback with all of these methods is the insufficient uptake and expression of selected genes (DNA). Gene delivery and transfection can be enhanced by the use of hypoxic injury and immunoliposomes as targeting modality. Transmission electron micrographs showed that immunoliposomes can be used to deliver hundreds or more units of intraliposomal contents into an individual target cell (FIG. 8).

<u>Current US Original Classification</u> (1): 424/450

WEST

Generate Collection

Print

Search Results - Record(s) 31 through 42 of 42 returned.

☐ 31. Document ID: US 5837283 A

L4: Entry 31 of 42

File: USPT

Nov 17, 1998

US-PAT-NO: 5837283

DOCUMENT-IDENTIFIER: US 5837283 A

TITLE: Cationic lipid compositions targeting angiogenic endothelial cells

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION: ·

NAME CITY STATE ZIP CODE COUNTRY

McDonald; Donald M. San Francisco CA
McLean; John Redwood City CA
Thurston; O. Gavin San Francisco CA

Baluk; Peter San Francisco CA

US-CL-CURRENT: 424/450

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw. Desc Image

KWAC

1 32. Document ID: US 5827703 A

L4: Entry 32 of 42

File: USPT

Oct 27, 1998

KWIC

US-PAT-NO: 5827703

DOCUMENT-IDENTIFIER: US 5827703 A

TITLE: Methods and composition for in vivo gene therapy

DATE-ISSUED: October 27, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Debs; Robert James Mill Valley CA Zhu; Ning El Cerrito CA

US-CL-CURRENT: 514/44; 424/417, 424/420, 424/450, 435/325, 435/354, 435/375, 435/458, 435/6, 435/69.1

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw, Desc Image

33. Document ID: US 5820879 A

L4: Entry 33 of 42

File: USPT

Oct 13, 1998

US-PAT-NO: 5820879

DOCUMENT-IDENTIFIER: US 5820879 A

TITLE: Method of delivering a lipid-coated condensed-phase microparticle composition

DATE-ISSUED: October 13, 1998

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Fernandez; Julio M. Knudson; Mark B.

Rochester Shoreview MN MN

US-CL-CURRENT: 424/450; 424/1.21, 424/489, 424/490, 424/9.4

Full Title Citation Front Review Classification Date Reference Sequences Attachments
Draw Desc Image

KWIC

☐ 34. Document ID: US 5814315 A

L4: Entry 34 of 42

File: USPT

Sep 29, 1998

US-PAT-NO: 5814315

DOCUMENT-IDENTIFIER: US 5814315 A

TITLE: Methods for the suppression of neu mediated phenotype in tumors

DATE-ISSUED: September 29, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Hung; Mien-Chie Houston TX
Yu; Di-Hua Houston TX
Matin; Angabin Houston TX
Zhang; Yujiao Joe Houston TX

US-CL-CURRENT: 424/93.2; 424/450, 424/93.6, 514/44

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

☐ 35. Document ID: US 5780052 A

L4: Entry 35 of 42

File: USPT

Jul 14, 1998

US-PAT-NO: 5780052

DOCUMENT-IDENTIFIER: US 5780052 A

TITLE: Compositions and methods useful for inhibiting cell death and for delivering

an agent into a cell

DATE-ISSUED: July 14, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Khaw; Ban An Milton MA
Torchilin; Vladmir P. Charlestown MA
Narula; Jagat Brookline MA
Vural; Imran Brookline MA

US-CL-CURRENT: 424/450; 436/829



7 36. Document ID: US 5753261 A

L4: Entry 36 of 42 File: USPT May 19, 1998

US-PAT-NO: 5753261

DOCUMENT-IDENTIFIER: US 5753261 A

TITLE: Lipid-coated condensed-phase microparticle composition

DATE-ISSUED: May 19, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Fernandez; Julio M. Rochester MN Knudson; Mark B. Shoreview MN

US-CL-CURRENT: 424/450; 424/489, 424/490



7 37. Document ID: US 5660855 A

L4: Entry 37 of 42 File: USPT Aug 26, 1997

US-PAT-NO: 5660855

DOCUMENT-IDENTIFIER: US 5660855 A

TITLE: Lipid constructs for targeting to vascular smooth muscle tissue

DATE-ISSUED: August 26, 1997

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Male-Brune; Roxanne Hillsborough NC

US-CL-CURRENT: 424/450; 514/24, 514/9

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

☐ 38. Document ID: US 5552155 A

L4: Entry 38 of 42

File: USPT

Sep 3, 1996

US-PAT-NO: 5552155

DOCUMENT-IDENTIFIER: US 5552155 A

TITLE: Fusogenic lipsomes and methods for making and using same

DATE-ISSUED: September 3, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Bailey; Austin L. Vancouver CA
Cullis; Pieter R. Vancouver CA

US-CL-CURRENT: 424/450; 428/402.2



☐ 39. Document ID: US 5169637 A

L4: Entry 39 of 42

File: USPT

Dec 8, 1992

US-PAT-NO: 5169637

DOCUMENT-IDENTIFIER: US 5169637 A

TITLE: Stable plurilamellar vesicles

DATE-ISSUED: December 8, 1992

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Lenk; Robert P. Lambertville NJ Fountain; Michael W. Griggstown NJ Janoff; Andrew S. Yardley PA Popescu; Mircea C. Plainsboro NJ Weiss; Steven J. Hightstown NJ Ginsberg; Richard S. Monroe Township, Salem County NJ

Ostro; Marc J. Griggstown NJ Gruner; Sol M. Lawrenceville NJ

US-CL-CURRENT: 424/450; 514/152, 514/192, 514/2, 514/29, 514/39, 514/41

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draws Description

☐ 40. Document ID: US 5030453 A

L4: Entry 40 of 42 File: USPT Jul 9, 1991

US-PAT-NO: 5030453

DOCUMENT-IDENTIFIER: US 5030453 A

TITLE: Stable plurilamellar vesicles

DATE-ISSUED: July 9, 1991

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Lenk; Robert P. Lambertville NJ Fountain; Michael W. Griggstown NJ Janoff; Andrew S. Yardley PA Popescu; Mircea C. Plainsboro ŊJ Weiss; Steven J. Hightstown NJ Monroe Township, Ginsberg; Richard S. NJ Ostro; Marc J. Griggstown NJ Gruner; Sol M. Lawrenceville NJ

US-CL-CURRENT: 424/450

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

☐ 41. Document ID: US 4708861 A

L4: Entry 41 of 42 File: USPT Nov 24, 1987

US-PAT-NO: 4708861

DOCUMENT-IDENTIFIER: US 4708861 A

TITLE: Liposome-gel compositions

DATE-ISSUED: November 24, 1987

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Popescu; Mircea C. Plainsboro NJ
Weiner; Alan L. Plainsboro NJ
Carpenter-Green; Sharon S. East Windsor NJ

US-CL-CURRENT: $\frac{424}{1.21}$; $\frac{264}{4.1}$, $\frac{264}{4.32}$, $\frac{424}{1.25}$, $\frac{424}{450}$, $\frac{424}{457}$, $\frac{424}{458}$, $\frac{424}{460}$, $\frac{424}{462}$, $\frac{424}{484}$, $\frac{428}{402.2}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw, Desc Image

☐ 42. Document ID: US 4684625 A

L4: Entry 42 of 42 File: USPT Aug 4, 1987

US-PAT-NO: 4684625

DOCUMENT-IDENTIFIER: US 4684625 A

TITLE: Method for enhancing the anti-infective activity of muramyldipeptide

derivatives


DATE-ISSUED: August 4, 1987

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Eppstein; Deborah A. Palo Alto CA Fraser-Smith; Elizabeth Los Altos CA Matthews; Thomas R. Los Gatos CA

US-CL-CURRENT: 514/19; 424/450, 514/8, 536/4.1, 536/53



Display Format: - Change Format

Previous Page Next Page

WEST

Generate Collection

Print

Search Results - Record(s) 1 through 30 of 42 returned.

☐ 1. Document ID: US 6465007 B1

L4: Entry 1 of 42

File: USPT

Oct 15, 2002

US-PAT-NO: 6465007

DOCUMENT-IDENTIFIER: US 6465007 B1

TITLE: Transgene expression in polarized cells

DATE-ISSUED: October 15, 2002

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Eastman; Simon J. Hudson MA
Chu; Quiming Melrose MA
Tousignant; Jennifer D. Cambridge MA
Cheng; Seng H. Wellesley MA
Scheule; Ronald K. Hopkinton MA

US-CL-CURRENT: <u>424/450</u>; <u>424/93.1</u>, <u>424/93.2</u>, <u>424/93.6</u>, <u>435/320.1</u>, <u>435/325</u>, <u>435/455</u>, <u>435/456</u>, <u>514/2</u>, <u>514/44</u>

Full Title Citation Front Review Classification Date Reference Sequences Attachments
Draw, Desc Image

KMIC

☐ 2. Document ID: US 6447801 B1

L4: Entry 2 of 42

File: USPT

Sep 10, 2002

US-PAT-NO: 6447801

DOCUMENT-IDENTIFIER: US 6447801 B1

TITLE: Anti-parasitic action of N,N-diethyl-m-toluamide (deet) and formulations that prolong its activity in the skin

DATE-ISSUED: September 10, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Salafsky; Bernard Rockford IL 61114 Kalyanasundaram; Ramaswamy Rockford IL 61107

Shibuya; Takeshi Tokyo JP

US-CL-CURRENT: 424/450; 424/405, 424/406, 424/408, 424/DIG.10, 514/617, 514/875,

514/919

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw, Desc Image

3. Document ID: US 6410049 B1

L4: Entry 3 of 42

File: USPT

Jun 25, 2002

US-PAT-NO: 6410049

DOCUMENT-IDENTIFIER: US 6410049 B1

TITLE: Preparation of stable formulations of lipid-nucleic acid complexes for

efficient in vivo delivery

DATE-ISSUED: June 25, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Papahadjopoulos; Demetrios San Francisco CA
Hong; Keelung San Francisco CA
Zheng; Weiwen San Francisco CA

US-CL-CURRENT: 424/450; 536/23.1

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw, Desc Image

4. Document ID: US 6358523 B1

L4: Entry 4 of 42

File: USPT

Mar 19, 2002

US-PAT-NO: 6358523

DOCUMENT-IDENTIFIER: US 6358523 B1

TITLE: Macromolecule-lipid complexes and methods for making and regulating

DATE-ISSUED: March 19, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Safinya; Cyrus R. Santa Barbara CA

Raedler; Joachim Oskar Garching DE

Koltover; Ilya Pasadena CA

US-CL-CURRENT: <u>424/450</u>; <u>424/400</u>, <u>424/405</u>, <u>424/484</u>, <u>424/9.1</u>

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

5. Document ID: US 6350853 B1

L4: Entry 5 of 42 File: USPT Feb 26, 2002

US-PAT-NO: 6350853

DOCUMENT-IDENTIFIER: US 6350853 B1

TITLE: Conjugated peptide nucleic acids having enhanced cellular uptake

DATE-ISSUED: February 26, 2002

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Nielsen; Peter E. Kokkedal DK Knudsen; Helle Copenhagen DK

US-CL-CURRENT: $\underline{530/300}$; $\underline{424/450}$, $\underline{536/23.1}$, $\underline{536/24.3}$, $\underline{536/24.5}$

CITY

Full Title Citation Front Review Classification Date Reference Sequences Attachments RWC Draw, Description

[6. Document ID: US 6331524 B1

L4: Entry 6 of 42 File: USPT Dec 18, 2001

STATE

MA

ZIP CODE

COUNTRY

US-PAT-NO: 6331524

DOCUMENT-IDENTIFIER: US 6331524 B1

TITLE: Organ-specific targeting of cationic amphiphile / DNA complexes for gene

therapy

NAME

DATE-ISSUED: December 18, 2001

INVENTOR-INFORMATION:

Scheule; Ronald K. Hopkinton MA Bagley; Rebecca G. Natick MA Eastman; Simon J. Hudson MA Cheng; Seng H. Wellesley MA Marshall; John Hopedale MA Harris; David J. Lexington MA Lee; Edward R. Natick MA Siegel; Craig S. Woburn MA Chang; Chau-Dung Lexington MA Hubbard; S. Catherine Belmont MA

Johnson; Duane E. Encinitas CA

Maneval; Daniel C. San Diego CA Shepard; H. Michael Rancho Santa Fe CA

Gregory; Richard J. Westford

US-CL-CURRENT: <u>514/44</u>; <u>424/450</u>, <u>435/320.1</u>, <u>435/455</u>, <u>435/458</u>

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

7. Document ID: US 6326356 B1

L4: Entry 7 of 42

File: USPT

Dec 4, 2001

US-PAT-NO: 6326356

DOCUMENT-IDENTIFIER: US 6326356 B1

TITLE: Suppression of new overexpression using a mini-ElA gene

DATE-ISSUED: December 4, 2001

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Hung; Mein-Chie Houston TX Chen; Hua Houston TX Yu; Dihua Houston TX

US-CL-CURRENT: 514/44; 424/450, 424/93.2, 424/93.6



8. Document ID: US 6320017 B1

L4: Entry 8 of 42 File: USPT Nov 20, 2001

US-PAT-NO: 6320017

DOCUMENT-IDENTIFIER: US 6320017 B1

TITLE: Polyamide oligomers

DATE-ISSUED: November 20, 2001

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Ansell; Steven Michial Vancouver CA

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

☐ 9. Document ID: US 6287591 B1

L4: Entry 9 of 42 File: USPT Sep 11, 2001

US-PAT-NO: 6287591

DOCUMENT-IDENTIFIER: US 6287591 B1

TITLE: Charged therapeutic agents encapsulated in lipid particles containing four

lipid components

DATE-ISSUED: September 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Semple; Sean C.	Vancouver			CA
Klimuk; Sandra K.	N. Vancouver			CA
Harasym; Troy	Vancouver			CA
Hope; Michael J.	Vancouver			CA
Ansell; Steven M.	Vancouver			CA
Cullis; Pieter	Vancouver			CA
Scherrer; Peter	Vancouver			CA
Debeyer; Dan	Vancouver			CA

US-CL-CURRENT: 424/450; 428/402.2, 435/177, 435/458, 514/44, 536/22.1



☐ 10. Document ID: US 6245520 B1

L4: Entry 10 of 42

File: USPT

Jun 12, 2001

US-PAT-NO: 6245520

DOCUMENT-IDENTIFIER: US 6245520 B1

TITLE: Methods for introducing nucleic acids into mammalian cells using imidazolium

lipids

DATE-ISSUED: June 12, 2001

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Wang; Jinkang San Francisco CA
Niven; Ralph Redwood City CA
Zhang; Yilin San Mateo CA
Huang; Pingzhong Apex NC

US-CL-CURRENT: $\frac{435}{6}$; $\frac{424}{450}$, $\frac{435}{320.1}$, $\frac{435}{375}$, $\frac{435}{455}$, $\frac{435}{458}$, $\frac{435}{69.1}$, $\frac{435}{70.1}$, $\frac{435}{91.1}$, $\frac{514}{400}$, $\frac{514}{44}$, $\frac{548}{349.1}$



☐ 11. Document ID: US 6210708 B1

L4: Entry 11 of 42

File: USPT

Apr 3, 2001

US-PAT-NO: 6210708

DOCUMENT-IDENTIFIER: US 6210708 B1

TITLE: Cationic virosomes as transfer system for genetic material

DATE-ISSUED: April 3, 2001

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Walti; Ernst Rudolf Munchenbuchsee CH
Gluck; Reinhard Spiegel bei Bern CH
Klein; Peter Langenbruck CH

US-CL-CURRENT: 424/450; 435/458

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMIC Draw, Desc Image

☐ 12. Document ID: US 6210707 B1

L4: Entry 12 of 42 File: USPT Apr 3, 2001

US-PAT-NO: 6210707

DOCUMENT-IDENTIFIER: US 6210707 B1

TITLE: Methods of forming protein-linked lipidic microparticles, and compositions

thereof

DATE-ISSUED: April 3, 2001

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Papahadjopoulos;DemetriosSan FranciscoCAHong;KeelungSan FranciscoCAZheng;WeiwenSan FranciscoCAKirpotin;Dmitri B.San FranciscoCA

US-CL-CURRENT: 424/450; 435/440, 435/6, 435/7.1, 435/7.2

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMC |
Draw Desc Image

☐ 13. Document ID: US 6197754 B1

L4: Entry 13 of 42 File: USPT Mar 6, 2001

US-PAT-NO: 6197754

DOCUMENT-IDENTIFIER: US 6197754 B1

TITLE: Suppression of tumor growth by a mini-E1A gene


DATE-ISSUED: March 6, 2001

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Hung; Mien-Chie Houston TX
Chen; Hua Houston TX
Yu; Di-hua Houston TX

US-CL-CURRENT: 514/44; 424/450, 424/93.2, 424/93.6



☐ 14. Document ID: US 6147204 A

L4: Entry 14 of 42

File: USPT

Nov 14, 2000

US-PAT-NO: 6147204

DOCUMENT-IDENTIFIER: US 6147204 A

TITLE: Nucleic acid ligand complexes

DATE-ISSUED: November 14, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Gold; Larry Boulder CO Schmidt; Paul G Niwot CO Janjic; Nebojsa Boulder CO

US-CL-CURRENT: 536/24.5; 424/450, 435/6, 435/91.2, 436/6, 536/25.4



☐ 15. Document ID: US 6121457 A

L4: Entry 15 of 42

File: USPT

Sep 19, 2000

US-PAT-NO: 6121457

DOCUMENT-IDENTIFIER: US 6121457 A

TITLE: Compositions and methods using novel substituted imidazolium lipids

DATE-ISSUED: September 19, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Wang; Jinkang San Francisco CA
Niven; Ralph Redwood City CA
Zhang; Yilin San Mateo CA
Huang; Pingzhong Apex NC

US-CL-CURRENT: <u>548/350.1</u>; <u>424/450</u>, <u>435/320.1</u>, <u>435/375</u>, <u>435/455</u>, <u>435/6</u>, <u>435/69.1</u>, <u>435/70.1</u>, <u>435/91.1</u>, <u>548/349.1</u>

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw, D	esc li	mage								

☐ 16. Document ID: US 6120799 A

L4: Entry 16 of 42

File: USPT

Sep 19, 2000

US-PAT-NO: 6120799

DOCUMENT-IDENTIFIER: US 6120799 A

TITLE: Cationic lipid compositions targeting angiogenic endothelial cells

DATE-ISSUED: September 19, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

McDonald; Donald M. San Francisco CA
McLean; John Redwood City CA
Thurston; O. Gavin San Francisco CA
Baluk; Peter San Francisco CA

US-CL-CURRENT: 424/450



☐ 17. Document ID: US 6110745 A

L4: Entry 17 of 42 ' File: USPT Aug 29, 2000

US-PAT-NO: 6110745

DOCUMENT-IDENTIFIER: US 6110745 A

TITLE: Preparation of lipid-nucleic acid particles using a solvent extraction and

direct hydration method

DATE-ISSUED: August 29, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Zhang; Yuan-Peng Mountain View CA

Scherrer; Peter Vancouver CA Hope; Michael J. Vancouver CA

US-CL-CURRENT: $\frac{435}{458}$; $\frac{264}{4 \cdot 1}$, $\frac{424}{450}$, $\frac{424}{93 \cdot 2}$, $\frac{435}{320 \cdot 1}$, $\frac{435}{325}$, $\frac{435}{91 \cdot 1}$, $\frac{43$

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMC |
Drawl Desc | Image |

☐ 18. Document ID: US 6086913 A

L4: Entry 18 of 42 File: USPT Jul 11, 2000

US-PAT-NO: 6086913

DOCUMENT-IDENTIFIER: US 6086913 A

TITLE: Liposomal delivery of AAV vectors

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Tam; Patrick Vancouver CA Chonn; Arcadio Vancouver CA

US-CL-CURRENT: 424/450; 435/235.1, 435/320.1, 435/458, 435/69.1, 536/23.2, 536/23.7

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

19. Document ID: US 6071533 A

L4: Entry 19 of 42 File: USPT Jun 6, 2000

US-PAT-NO: 6071533

DOCUMENT-IDENTIFIER: US 6071533 A

TITLE: Preparation of stable formulations of lipid-nucleic acid complexes for

efficient in vivo delivery

DATE-ISSUED: June 6, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Papahadjopoulos; Demetrios San Francisco CA
Hong; Keelung San Francisco CA
Zheng; Weiwen San Francisco CA

US-CL-CURRENT: 424/450

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC |
Draw Desc | Image |

20. Document ID: US 6043094 A

L4: Entry 20 of 42 File: USPT Mar 28, 2000

US-PAT-NO: 6043094

DOCUMENT-IDENTIFIER: US 6043094 A

TITLE: Therapeutic liposome composition and method


DATE-ISSUED: March 28, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Martin; Francis J. San Francisco CA Zalipsky; Samuel Redwood City CA Huang; Shi Kun Castro Valley CA

US-CL-CURRENT: 435/458; 424/450, 435/375, 530/402, 530/403



☐ 21. Document ID: US 6011020 A

L4: Entry 21 of 42

File: USPT

Jan 4, 2000

US-PAT-NO: 6011020

DOCUMENT-IDENTIFIER: US 6011020 A

TITLE: Nucleic acid ligand complexes

DATE-ISSUED: January 4, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Gold; Larry Boulder CO Schmidt; Paul G. San Marino CA Janjic; Nebojsa Boulder CO

US-CL-CURRENT: 514/44; 424/1.21, 424/1.73, 424/450, 435/6, 536/22.1, 536/23.1, 536/24.3,



☐ 22. Document ID: US 6001644 A

L4: Entry 22 of 42 File: USPT Dec 14, 1999

US-PAT-NO: 6001644

DOCUMENT-IDENTIFIER: US 6001644 A

TITLE: Mammalian transformation complex comprising a lipid carrier and DNA encoding

CFTR

DATE-ISSUED: December 14, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Debs; Robert J. Mill Valley CA
Zhu; Ning El Cerrito CA

US-CL-CURRENT: $\underline{435}/\underline{320.1}$; $\underline{128}/\underline{203.22}$, $\underline{424}/\underline{450}$, $\underline{435}/\underline{458}$, $\underline{514}/\underline{44}$, $\underline{600}/\underline{243}$, $\underline{600}/\underline{249}$, $\underline{601}/\underline{1}$



☐ 23. Document ID: US 5981501 A

L4: Entry 23 of 42 File: USPT Nov 9, 1999

US-PAT-NO: 5981501

DOCUMENT-IDENTIFIER: US 5981501 A

TITLE: Methods for encapsulating plasmids in lipid bilayers

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Wheeler; Jeffery J. Richmond CA

Hope; Michael Vancouver CA
Cullis; Pieter R. Vancouver CA
Bally; Marcel B. Bowen Island CA

US-CL-CURRENT: <u>514/44</u>; <u>264/4.3</u>, <u>264/4.6</u>, <u>424/450</u>, <u>436/829</u>, <u>514/55</u>, <u>514/851</u>

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw, Desc Image

☐ 24. Document ID: US 5980935 A

L4: Entry 24 of 42 File: USPT Nov 9, 1999

US-PAT-NO: 5980935

DOCUMENT-IDENTIFIER: US 5980935 A

TITLE: Cationic lipids and methods of use therefor

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Kirpotin; Dmitri San Fransisco CA 94121 Chan; Daniel C. F. Denver CO 80237 Bunn; Paul Evergreen CO 80439

US-CL-CURRENT: 424/450

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw, Desc Image

25. Document ID: US 5976567 A

L4: Entry 25 of 42 File: USPT Nov 2, 1999

US-PAT-NO: 5976567

DOCUMENT-IDENTIFIER: US 5976567 A

TITLE: Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid

complex intermediate and use for gene transfer

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

ZIP CODE COUNTRY CITY STATE NAME Richmond CA Wheeler; Jeffery J. CA Bally; Marcel B. Bowen Island CA Vancouver Zhang; Yuan-Peng Reimer; Dorothy L. CA Vancouver CA Hope; Michael Vancouver CA Cullis; Pieter R. Vancouver Vancouver CA Scherrer; Peter

US-CL-CURRENT: 424/450; 435/458, 514/44



☐ 26. Document ID: US 5965542 A

L4: Entry 26 of 42

File: USPT

Oct 12, 1999

US-PAT-NO: 5965542

DOCUMENT-IDENTIFIER: US 5965542 A

TITLE: Use of temperature to control the size of cationic liposome/plasmid DNA complexes

DATE-ISSUED: October 12, 1999

INVENTOR-INFORMATION:

NAME ZIP CODE COUNTRY CITY STATE CA Wasan; Ellen K. Vancouver Bally; Marcel B. Bowen Island CA Hope; Michael J. Vancouver CA CA Reimer; Dorothy L. Vancouver Ahkong; Quet Fah CA Surry

US-CL-CURRENT: 514/44; 424/450, 435/320.1, 435/458, 435/468, 435/91.1, 435/91.4, 536/23.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw, D	esc	mage								

☐ 27. Document ID: US 5955365 A

L4: Entry 27 of 42

File: USPT

Sep 21, 1999

US-PAT-NO: 5955365

DOCUMENT-IDENTIFIER: US 5955365 A

TITLE: Self-assembling polynucleotide delivery system

DATE-ISSUED: September 21, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Szoka, Jr.; Francis C. San Francisco CA Haensler; Jean San Francisco CA

US-CL-CURRENT: 435/441; 424/450, 435/440, 435/443, 435/455, 435/458, 435/466, 514/44, 536/24.5

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw, Desc Image

☐ 28. Document ID: US 5939401 A

L4: Entry 28 of 42 File: USPT Aug 17, 1999

US-PAT-NO: 5939401

DOCUMENT-IDENTIFIER: US 5939401 A

TITLE: Cationic amphiphile compositions for intracellular delivery of therapeutic

molecules

DATE-ISSUED: August 17, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Marshall; John Milford MA Harris; David J. Lexington MA Lee; Edward R. MA Quincy Siegel; Craig S. MA Woburn Eastman; Simon J. Marlboro MA Chang; Chau-Dung Lexington MA Scheule; Ronald K. Hopkinton MA Cheng; Seng H. Wellesley MA

US-CL-CURRENT: 514/44; 424/450, 514/2, 552/544

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw, Description

☐ 29. Document ID: US 5908777 A

L4: Entry 29 of 42 File: USPT Jun 1, 1999

US-PAT-NO: 5908777

DOCUMENT-IDENTIFIER: US 5908777 A

TITLE: Lipidic vector for nucleic acid delivery

DATE-ISSUED: June 1, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Lee; Robert J. Pittsburgh PA Huang; Leaf Wexford PA US-CL-CURRENT: $\underline{435}/\underline{320.1}$; $\underline{264}/\underline{4.1}$, $\underline{424}/\underline{450}$, $\underline{424}/\underline{93.21}$, $\underline{435}/\underline{325}$, $\underline{435}/\underline{458}$, $\underline{435}/\underline{69.1}$, $\underline{514}/\underline{44}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments KAAC Draw Desc Image ☐ 30. Document ID: US 5891689 A L4: Entry 30 of 42 File: USPT Apr 6, 1999 US-PAT-NO: 5891689 DOCUMENT-IDENTIFIER: US 5891689 A TITLE: Heme-bearing microparticles for targeted delivery of drugs DATE-ISSUED: April 6, 1999 INVENTOR-INFORMATION: COUNTRY CITY STATE ZIP CODE NAME Takle; Garry B. New York NY George; Shaji T. New York NY US-CL-CURRENT: 435/458; 424/450, 435/174, 435/456, 514/44Full Title Citation Front Review Classification Date Reference Sequences Attachments KWIC **Generate Collection** Print **Terms Documents** L3 and ((424/450)!.CCLS.) 42

Display Format: - Change Format

Previous Page Next Page

WEST Search History

DATE: Tuesday, January 07, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB = USPT	JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR		
L4	L3 and ((424/450)!.CCLS.)	42	L4
L3	(cationic adj1 liposome\$) and label	406	L3
L2	(cationic adj1 liposome\$) and label\$	1034	L2
L1	(cationic adj1 liposome\$) same label	5	L1

END OF SEARCH HISTORY